Pamiparib

Pamiparib is an orally bioavailable inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, which are involved in a number of cellular processes, including DNA repair. It is being investigated for its potential use in the treatment of various types of cancer.

Mechanism of Action

Pamiparib works by inhibiting the activity of PARP enzymes, particularly PARP1 and PARP2. These enzymes play a critical role in the repair of single-strand breaks in DNA. By inhibiting PARP, pamiparib prevents the repair of these DNA breaks, leading to the accumulation of DNA damage, which can result in cell death. This mechanism is particularly effective in cancer cells that are already deficient in other DNA repair pathways, such as those with BRCA1 or BRCA2 mutations.

Clinical Development

Pamiparib is currently undergoing clinical trials to evaluate its efficacy and safety in the treatment of various cancers, including ovarian cancer, breast cancer, and gastric cancer. Early-phase clinical trials have shown promising results, with some patients experiencing significant tumor shrinkage and prolonged progression-free survival.

Side Effects

As with other PARP inhibitors, pamiparib can cause a range of side effects. Common side effects include nausea, fatigue, anemia, and thrombocytopenia. More serious side effects can include myelodysplastic syndrome and acute myeloid leukemia, although these are relatively rare.

Research and Future Directions

Ongoing research is focused on identifying biomarkers that can predict which patients are most likely to benefit from pamiparib treatment. Additionally, combination therapies involving pamiparib and other anticancer agents are being explored to enhance its therapeutic efficacy.

See Also

• PARP inhibitor
• BRCA mutation
• DNA repair
• Ovarian cancer
• Breast cancer
• Gastric cancer